https://www.biospace.com/bioinvent-and-transgene-first-patient-treated-in-part-b-of-phase-1-trial-assessing-the-novel-oncolytic-virus-bt-001-in-combination-with-keytruda-pembrolizumab
BioInvent and Transgene: First patient treated in Part B of Phase 1 trial assessing the novel...
Oct 10, 2023 - BioInvent International AB and Transgene announce that that the first patient of the Phase 1 part B clinical trial evaluating the combination of BT-001 and...
https://www.biospace.com/bioinvent-to-hold-two-poster-presentations-at-sitc-38th-annual-meeting
BioInvent to Hold Two Poster Presentations at SITC 38th Annual Meeting - BioSpace
Sep 28, 2023 - BioInvent International announces it will hold two poster presentations on its anti-tumor necrosis factor receptor 2 programs at the Society of Immunotherapy...
poster presentations
https://www.biospace.com/bioinvent-expands-the-development-program-for-bi-1206-with-a-new-clinical-trial
BioInvent Expands The Development Program for BI-1206 With A New Clinical Trial - BioSpace
Oct 27, 2017 - Comments from the CEO: "During the third quarter of 2017, BioInvent has initiated preparations for a clinical trial with BI-1206 in combination with rituximab...
https://www.biospace.com/press-releases/bioinvent-international-ab-interim-report-january-march-2025
BioInvent International AB: Interim Report January - March 2025 - BioSpace
interim reportmarch 2025bioinventinternationalab
https://www.ig.com/ae/shares/markets-shares/bioinvent-international-ab-BINV-SE
Trade BioInvent International AB (publ) Shares | Live BioInvent International AB (publ) Share Price...
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing... [AE]
live sharetradebioinventinternationalab
https://www.fiercebiotech.com/biotech/exelixis-forks-over-25m-licensing-rights-potential-bioinvent-antibody-drug-targets
Exelixis signs on $25M to check out BioInvent's antibody library
Jun 16, 2022 - Exelixis will pay $25 million upfront for the right to check out three drug targets from BioInvent's library.
check outexelixissigns25m
https://www.biospace.com/press-releases/transgene-and-bioinvent-to-present-updated-data-on-armed-oncolytic-virus-bt-001-at-esmo-2025
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025 -...
https://www.biospace.com/bioinvent-announces-abstract-presentation-of-bi-1206-at-the-17th-international-conference-of-malignant-lymphoma-2023
BioInvent Announces Abstract Presentation of BI-1206 at the 17th International Conference of...
Jun 13, 2023 - BioInvent International Abstract for the ongoing clinical trial with BI-1206 in combination with rituximab has been accepted to the ICML and showcases the...
abstract presentation
https://www.prnewswire.co.uk/news-releases/bioinvent-receives-milestone-payment-related-to-tak-169-investigational-new-drug-application-814120628.html
BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application
/PRNewswire/ -- BioInvent International AB (BINV) today announced it will receive a $0.5 million milestone payment related to the acceptance by the U.S. Food...
investigational new drug
https://www.digitaljournal.com/pr/news/accesswire/bioinvent-presents-positive-first-clinical-data-on-anti-fcyriib-antibody-bi-1607
BioInvent Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607
clinical data
https://simplywall.st/stocks/se/pharmaceuticals-biotech/sto-binv/bioinvent-international-shares/news/bioinvent-international-ab-publs-stobinv-ceo-might-not-expec
BioInvent International AB (publ)'s (STO:BINV) CEO Might Not Expect Shareholders To Be So Generous...
Key Insights BioInvent International will host its Annual General Meeting on 29th of April Salary of kr2.96m is part of...
https://www.businesswire.com/news/home/20231009505229/en/Transgene-and-BioInvent---First-Patient-Treated-in-Part-B-of-Phase-I-Trial-Assessing-the-Novel-Oncolytic-Virus-BT-001-in-Combination-With-KEYTRUDA-pembrolizumab
Transgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel...
Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent In...
https://www.ig.com/jp/shares/markets-shares/bioinvent-international-ab-BINV-SE
BioInvent International AB (publ)
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing... [JP]
bioinventinternationalabpubl
https://www.southampton.ac.uk/research/projects/cragg-bioinvent-antibody-hub
Cragg - Bioinvent - Antibody Hub | University of Southampton
Cragg - Bioinvent - Antibody Hub.
university ofcraggbioinventantibodyhub
https://www.accessnewswire.com/newsroom/en/biotechnology/bioinvent-to-participate-in-upcoming-investor-conferences-1023514
BioInvent to Participate in Upcoming Investor Conferences
LUND, SE / ACCESS Newswire / May 5, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and...
to participatebioinventupcominginvestorconferences